IS THE PATIENT PARTNERSHIP INFORMATIVE IN PHARMACOVIGILANCE?
https://doi.org/10.14412/1995-4484-2017-449-451
Abstract
The paper discusses whether patients' spontaneous reporting on adverse drug reactions is appropriate and possible.
About the Author
Yu. V. Muravyev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Wooten JM. Adverse drug reactions: part I. South Med J. 2010;103(10):1025-8. doi: 10.1097/SMJ.0b013e3181f0c866
2. WHO Technical Report. 1972;498.
3. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis and management. Lancet. 2000;356:1255-9. doi: 10.1016/S0140-6736(00)02799-9
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-5. doi: 10.1001/jama.279.15.1200
5. Watson R. New EU drug safety committee ends national reporting of drug reactions. BMJ. 2012;345:e4690. doi: 10.1136/bmj.e4690
6. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017-25. doi: 10.1345/aph.1L037
7. Bordet R, Gautier S, Le Louet H, et al. Analysis of the direct cost of adverse drug reactions in hospitalized patients. Eur J Clin Pharmacol. 2001;56(12):935-41. doi: 10.1007/s002280000260
8. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29-34. doi: 10.1001/jama.1995.03530010043033
9. Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. BMC Clin Pharmacol. 2009;9:14. doi: 10.1186/1472-6904-9-14
10. Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf. 2009;32(11):1067-74. doi: 10.2165/11316680-000000000-00000
11. Van Puijenbroek E, Diemont W, van Grootheest K. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf. 2003;26(5):293-301. doi: 10.2165/00002018-200326050-00001
12. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ. 2004;329(7456):44-7. doi: 10.1136/bmj.329.7456.44
13. Sharrar RG, Dieck GS. Monitoring product safety in the postmarketing environment. Ther Adv Drug Saf. 2013;4(5):211-9. doi: 10.1177/2042098613490780
14. Herdeiro MT, Figueiras A, Polonia J, Gestal-Otero J. Influence of pharmacists' attitudes on adverse drug reaction reporting. Drug Saf. 2006;29(4):331-40. doi: 10.2165/00002018- 200629040-00004
15. Olsson S. The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Saf. 1998;19:1-10. doi: 10.2165/00002018- 199819010-00001
16. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006,29:385-96. doi: 10.2165/00002018-200629050-00003
17. Biagi C, Montanaro N, Buccellato E, et al. Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia- Romagna region). Eur J Clin Pharmacol. 2013;69(2):237- 44. doi: 10.1007/s00228-012-1321-7
18. Alvarez-Requejo A, Carvajal A, Begaud B, et al. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol. 1998,54:483-8. doi: 10.1007/s002280050498
19. Meyboom RH, Egberts AC, Gribnau FW, Hekster YA. Pharmacovigilance in perspective. Drug Safety. 1999;21(6):429-47. doi: 10.2165/00002018-199921060-00001
20. Inman WH. Attitudes to adverse drug reaction reporting. Br J Clin Pharmacol. 1996;41:434-5.
21. Backstrom M, Mjorndal T, Dahlqvist R. Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf. 2004;13:483-7. doi: 10.1002/pds.962
22. Herxheimer A, Crombag R, Alves TL. Patients reported adverse drug reactions: what's happening in Europe. Assist Inferm Ric. 2011;30(1):42-7.
23. Mitchell AS, Henry DA, Sanson-Fisher R, O'Connell DL. Patients as a direct source of information on adverse drug reactions. BMJ (Clinical research ed). 1988;297(6653):891-3. doi: 10.1136/bmj.297.6653.891
24. Hazell L, Cornelius V, Hannaford P, et al. How do patients contribute to signal detection? A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme. Drug Saf. 2013;36(3):199-206. doi: 10.1007/s40264-013-0021-2
25. Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2006;63:148-56. doi: 10.1111/j.1365-2125.2006.02746.x
26. Van Grootheest K, de Graafde L, de Jong-van den Berg LT. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf Int J Med Toxicol Drug Exp. 2003;26(4):211- 7. doi: 10.2165/00002018-200326040-00001
27. Aagaard L, Hansen EH. Consumers' reports of suspected adverse drug reactions volunteered to a consumer magazine. Br J Clin Pharmacol. 2010;69(3):317-8. doi: 10.1111/j.1365-2125.2009.03584.x
28. Aronson J. Risk perception in drug therapy. Br J Clin Pharmacol. 2006;62(2):135-7. doi: 10.1111/j.1365-2125.2006.02739_1.x
29. Bongard V, Menard-Tache S, Bagheri H, et al. Perception of the risk of adverse drug reactions: ifferencesbetween health professionals and non health professionals. Br J Clin Pharmacol. 2002;54(4):433-06. doi: 10.1046/j.1365-2125.2002.01674.x
30. Matos C, van Hunsel F, Joaquim J. Are consumers ready to take part in the Pharmacovigilance System? – a Portuguese preliminary study concerning ADR reporting. Eur J Clin Pharmacol. 2015;71(7):883-90. doi: 10.1007/s00228-015-1867-2
31. World Health Organization website. http://apps.who.int/ medicinedocs/fr/d/Jh1465e/4.html. Accessed 20 Sept 2013.
32. Egberts TC, Smulders M, de Koning FH, et al. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ. 1996;313(7056):530-1. doi: 10.1136/bmj.313.7056.530
33. Van Hunsel F, Talsma A, van Puijenbroek E, et al. The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study. Pharmacoepidemiol Drug Saf. 2011;20(3):286-91. doi: 10.1002/pds.2092
34. Van Hunsel F, Passier A, van Grootheest AC. Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example. Br J Clin Pharmacol. 2009;67(5):558-64. doi: 10.1111/j.1365-2125.2009.03400.x
35. Inch J, Watson MC, Anakwe-Umeh S. Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review. Drug Saf. 2012;35(10):807-18. doi: 10.1007/BF03261977
36. Margraff F, Bertram D. Adverse drug reaction reporting by patients: an overview of fifty countries. Drug Saf. 2014 Jun;37(6):409-19. doi: 10.1007/s40264-014-0162-y
Review
For citations:
Muravyev Yu.V. IS THE PATIENT PARTNERSHIP INFORMATIVE IN PHARMACOVIGILANCE? Rheumatology Science and Practice. 2017;55(4):449-451. (In Russ.) https://doi.org/10.14412/1995-4484-2017-449-451
Views:
587
Email this article 